deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03865732

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment.

Sponsor: Marinus Pharmaceuticals

Updated 18 times since 2019 Last updated: Jun 20, 2023 Started: May 17, 2019 Primary completion: Jan 19, 2021 Completion: Jun 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on PCDH19-Related Epilepsy, this trial is completed. The trial is conducted by Marinus Pharmaceuticals and has accumulated 18 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2022 · 18 months · monthly snapshot~Sep 2022 – ~Jul 2023 · 10 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2022 — Jul 2023 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

Show 13 earlier versions
  1. Mar 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting · Phase: PHASE3PHASE2

  4. May 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  5. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  6. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  7. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  8. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  9. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  10. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  11. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  12. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  13. Apr 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Marinus Pharmaceuticals
Data source: Marinus Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .